Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)

Atea Pharmaceuticals has reported Current Deferred Revenue over the past 2 years, most recently at $192.2 million for Q3 2021.

  • Quarterly results put Current Deferred Revenue at $192.2 million for Q3 2021, changed N/A from a year ago — trailing twelve months through Sep 2021 was $192.2 million (changed N/A YoY), and the annual figure for FY2020 was $301.4 million, changed.
  • Current Deferred Revenue for Q3 2021 was $192.2 million at Atea Pharmaceuticals, down from $225.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for AVIR hit a ceiling of $301.4 million in Q4 2020 and a floor of $192.2 million in Q3 2021.